首页> 外文期刊>Critical care medicine >Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis
【24h】

Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis

机译:皮质类固醇作为辅助治疗流感的治疗方法:更新的Cochrane系统审查和Meta分析

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives: Corticosteroids may be beneficial in sepsis, but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence regarding corticosteroids in the treatment of influenza and examines the effect of dose on outcome. Data Sources: Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, and Web of Science) and trial registries were searched to October 2018 for randomized controlled trials, quasi-experimental designs, and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in individuals with influenza. Study Selection and Data Extraction: Two researchers independently assessed studies for inclusion. Risk of bias was assessed using the Cochrane Risk of Bias tool (randomized controlled trials) or Newcastle-Ottawa Scale (observational studies). Where appropriate, we estimated the effect of corticosteroids by random-effects meta-analyses using the generic inverse variance method. Meta-regression analysis was used to assess the association of corticosteroid dose and mortality. Data Synthesis: We identified 30 eligible studies, all observational apart from one randomized controlled trial. Twenty-one observational studies were included in the meta-analysis of mortality, which suggested an adverse association with corticosteroid therapy (odds ratio, 3.90; 95% CI, 2.31-6.60; 15 studies; adjusted hazard ratio, 1.49; 95% CI, 1.09-2.02; six studies). Risk of bias assessment was consistent with potential confounding by indication. Pooled analysis of seven studies showed increased odds of hospital-acquired infection in people treated with corticosteroids (unadjusted odds ratio, 2.74; 95% CI, 1.51-4.95). Meta-regression of the effect of dose on mortality did not reveal an association, but reported doses of corticosteroids in included studies were high (mostly > 40 mg methylprednisolone [or equivalent] per day). Conclusions: Corticosteroid treatment in influenza is associated with increased mortality and hospital-acquired infection, but the evidence relates mainly to high corticosteroid doses and is of low quality with potential confounding by indication a major concern.
机译:目的:皮质类固醇可能在败血症中有益,但不确定性仍然在严重流感上的影响。该系统评论更新了关于治疗流感的皮质类固醇的目前的证据,并检查剂量对结果的影响。数据来源:电子数据库(Medline,Embase,Cinahl,Lilacs,Central,Central和Web)和试验登记册进行了针对2018年10月,用于随机对照试验,准实验设计和观察队列研究报告皮质类固醇与皮质类固醇治疗具有流感的个体。学习选择和数据提取:两位研究人员独立评估了纳入的研究。使用偏置工具(随机对照试验)或纽卡斯尔 - 渥太华规模(观察研究)的Cochrane风险评估偏差风险。在适当的情况下,我们估计了通过使用通用逆变异法通过随机效应元分析的皮质类固醇的影响。 Meta回归分析用于评估皮质类固醇剂量和死亡率的关联。数据综合:我们确定了30个合格的研究,所有观察到除了一个随机对照试验之外。在死亡率的Meta分析中包含二十一项观察性研究,这表明与皮质类固醇治疗(赔率比,3.90; 95%CI,2.31-6.60; 15研究;调整后危险比,1.49; 95%CI, 1.09-2.02;六项研究)。偏见评估的风险与潜在的混淆一致。七项研究的汇总分析表明,用皮质类固醇治疗的人们(未调整的赔率比,2.74; 95%CI,1.51-4.95),增加了医院收购感染的几率。 Meta-返回剂量对死亡率的影响没有揭示一个关联,但报道的包括研究中的皮质类固醇剂量高(大多数> 40mg甲基己酮酮[或等同物])。结论:流感的皮质类固醇治疗与增加的死亡率和医院获得的感染有关,但证据主要涉及高皮质类固醇剂量,具有低质量,具有潜在的混淆,呈现主要关注。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号